tradmap

VIR Vir Biotechnology, Inc.

$9.15 -1.66%

Healthcare · Biological Products, (No Diagnostic Substances)

Vir Biotechnology, Inc. (VIR) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $1.5 billion. Shares last traded at $9.15, 31.7% below their 52-week high. Over the past year the stock is up 79.5%. Net profit margin is -638.9%, below the peer median of 6.3%. Revenue declined 7.6% year over year.

Market Cap
$1.5B
Shares Out
168.7M
EPS (TTM)
$-6.27
P/E Ratio
P/S Ratio
22.52
P/B Ratio
1.90
Dividend / Share
Dividend Yield
52-Week High
$13.41
52-Week Low
$4.16
Volume
125,950
Avg Vol (3m)
109,141.984

Performance

1W
+7.58%
1M
+6.95%
3M
-2.40%
6M
+41.28%
YTD
+53.87%
1Y
+79.51%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
52.74
SMA (50)
$9.48
SMA (200)
$7.48
Price vs SMA50
-3.40%
Price vs SMA200
+22.37%
ATR (14)
$0.48

Financials

Revenue
$69M
Net Income
$-438M
Gross Margin
Operating Margin
-699.2%
Net Margin
-638.9%
Return on Equity
-53.9%
Return on Assets
-42.7%
Current Ratio
7.11
Debt / Equity
0.26
Revenue Growth (YoY)
-7.6%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.85 2026-05-07
FY 2025 $-3.16 2026-02-23
Q3 2025 $-2.86 2025-11-05
Q2 2025 $-1.68 2025-08-06
Q1 2026 $-0.88 2026-05-07
FY 2025 $-3.83 2026-02-23

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

VIR vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
22.52 / 5.21 med
+332% premium
Net margin vs peers
-638.9% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.